STOCK TITAN

BULLFROG AI HLDGS INC - BFRG STOCK NEWS

Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.

BullFrog AI Holdings Inc. (NASDAQ: BFRG) is a biotechnology innovator using artificial intelligence to accelerate drug discovery and clinical development. This news hub provides investors and industry professionals with timely updates on the company's AI-driven research initiatives, strategic partnerships, and therapeutic advancements.

Access consolidated information on BFRG's latest press releases including clinical trial progress, regulatory milestones, and technology developments related to its proprietary bfLEAP platform. Our curated collection serves as an essential resource for tracking advancements in precision medicine and AI-powered pharmaceutical research.

Key updates cover therapeutic focus areas such as liver disease treatments, obesity research, and neuropsychiatric disorder solutions. Stay informed about collaborative projects with leading research institutions and data-driven breakthroughs in biomarker discovery.

Bookmark this page for direct access to BullFrog AI's official announcements and third-party analysis. Regularly updated content ensures you maintain current awareness of the company's position at the intersection of biotechnology and artificial intelligence innovation.

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has had an extraordinary year, marked by progress, innovation, and value-adding events. The company successfully completed an $8.4 million IPO listing on Nasdaq and secured an exclusive partnership with Lieber Institute for Brain Development. BullFrog AI has also made significant strides in drug development, including identifying drug targets for colorectal cancer and initiating pre-clinical studies for liver disease and obesity drug candidates. The company has strengthened its intellectual property, licensed improvements to its AI algorithms, and recorded its first earned revenue in the third quarter. BullFrog AI's CEO, Vin Singh, is optimistic about the future, emphasizing the company's focus on securing business and driving revenue through external contracts and partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
AI
-
Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced the launch of a preclinical study led by Dr. Randy Seeley to evaluate the efficacy of its drug candidate BF-114 in treating obesity, NAFLD, and NASH. The study is expected to be completed in Q2 2024 and aims to complement the company’s AI platform for identifying new pathways to target obesity and metabolic diseases. With the market for obesity drugs projected to exceed $77 billion by 2030, the potential impact of BF-114 on these conditions is significant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
-
Rhea-AI Summary
RedChip Companies will air interviews with ASP Isotopes Inc. and BullFrog AI Holdings, Inc. on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV. ASP Isotopes CEO provides a corporate update, highlighting the completion of the first manufacturing plant and securing multiple supply agreements. BullFrog AI Founder and CEO discusses the company's use of machine learning in drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
AI
Rhea-AI Summary
BullFrog AI Holdings, Inc. to present at Benzinga's All Access investor event
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences AI
-
Rhea-AI Summary
BullFrog AI identifies potential therapeutic targets for colorectal cancer using AI-driven platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
AI
-
Rhea-AI Summary
BullFrog AI's drug BF-223 shows anti-cancer activity against glioblastoma in animal model, with improved properties compared to BF-222
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.69%
Tags
Rhea-AI Summary
BullFrog AI founder and CEO to present at BioFuture 2023, discussing recent partnerships, revenue, growth strategy, and portfolio of prodrugs in early-stage clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences AI
-
Rhea-AI Summary
BullFrog AI launches BullFrog Data Networks, a comprehensive data network platform for disease indications, providing customized visual representation of relationships and pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
AI
-
Rhea-AI Summary
BullFrog AI founder and CEO to give virtual presentation at Maxim Group's 2023 Virtual Tech Conference Series, Emerging Growth in AI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
conferences acquisition AI
Rhea-AI Summary
BullFrog AI announces strategic partnership with LIBD to accelerate R&D initiatives using AI platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
partnership AI
BULLFROG AI HLDGS INC

Nasdaq:BFRG

BFRG Rankings

BFRG Stock Data

15.63M
6.97M
29.2%
11.72%
6.24%
Health Information Services
Pharmaceutical Preparations
Link
United States
GAITHERSBURG